Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06749210 · ClinicalTrials.gov registry record · Phase 2
Daance FOR Chemotherapy-induced Neuropathy
A Phase 2 study of Cancer of the Breast and Chemotherapy-induced Neuropathy, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 2
- Study locations
NCT06749210: Recruiting Phase 2 study of Cancer of the Breast and Chemotherapy-induced Neuropathy, sponsored by Ohio State University Comprehensive Cancer Center.
NCT06749210 is a Phase 2 study of Cancer of the Breast and Chemotherapy-induced Neuropathy that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 140 participants, below the 171-participant average among 15 other Cancer of the Breast trials with a reported enrollment target (18% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06749210, a Phase 2 study of Cancer of the Breast and Chemotherapy-induced Neuropathy, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 2
- Study locations
Study Summary
Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function while addressing patient-reported symptoms and participation in treatment. Toward this end, the investigators propose to study a noninvasive, social sensorimotor intervention - Adapted Argentine Tango - which targets motor control restoration, symptom alleviation, and treatment participation in concert.
Primary Outcome
Sensation of numbness/tingling on 0-10 scale; minimum value 0 (no numbness/tingling); maximum value 10 (worst numbness/tingling)
Conditions Studied
Interventions
- BEHAVIORAL Tango
Study Locations (2)
Connecticut
- Yale University - New Haven
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-02-19 |
| Est. Completion | 2029-08-15 |
| Phase | Phase 2 |
What NCT06749210 shows while recruiting
NCT06749210 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 171-participant average among 15 other Cancer of the Breast trials with a reported enrollment target (18% lower).
The record links to 2 conditions, with Cancer of the Breast appearing as the primary indexed condition, and to 1 intervention - of which Tango is the first listed.
NCT06749210 reports a single indexed study location in Connecticut, Ohio.
Frequently Asked Questions
What is clinical trial NCT06749210 about?
NCT06749210 is a clinical study titled "Daance FOR Chemotherapy-induced Neuropathy". Up to 80% of breast cancer survivors experience chemotherapy-induced neuropathy that impairs quality of life and increases fall risk long into survivorship, yet treatment options for neuropathy remain limited. The successful treatment will target neurophysiologic mechanisms for restoring function wh...
What is the current status of trial NCT06749210?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2025-02-19. Estimated completion is 2029-08-15.
What conditions does trial NCT06749210 study?
This clinical trial studies the following conditions: Cancer of the Breast, Chemotherapy-induced Neuropathy.
What interventions are being tested in trial NCT06749210?
The interventions under investigation include: Tango (BEHAVIORAL).
Who is sponsoring clinical trial NCT06749210?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06749210 being conducted?
This trial has 2 study locations across Connecticut, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of the Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06749210's enrollment target sits among peer trials
140 5th of 15 higher than 11 of 15 other Cancer of the Breast trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer of the Breast trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RECRUITING · Phase 2
-
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
RECRUITING · Phase 2
-
Proton Radiation for Stage II/III Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Axillary Reverse Mapping
ACTIVE NOT RECRUITING · Phase 2
-
Comparing Letrozole Given Alone to Letrozole Given With Avastin in Post-Menopausal Women Breast Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI